The present invention is intended to provide an existing therapeutic agent is different from the, new human T-cell leukemia virus-1 associated myelopathy (HAM) of patients and asymptomatic HTLV-1 carrier treatment methods and therapeutic agents to. The present invention provides anti-human CC-...
(ATLL)2and a range of debilitating neuromuscular disorders—HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP)3, which often lead to paralysis. Although only 5–10% of the estimated 10–20 million people4infected with HTLV-1 worldwide will develop ATLL2, a recent report showed ...
Human T-lymphotropic virus I (HTLV-1) is associated with the T-cell malignancy known as adult T-cell leukemia/ lymphoma (ATLL) and with a disorder called HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Currently, the treatment of these diseases is based on symptom relief...
HTLV-1 predominantly causes ATL and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). There are five different clinical stages of ATL: asymptomatic carrier state, preleukemic state, chronic/smoldering ATL, lymphoma type and acute ATL [48,49,50,51]. The majority of the HTLV-...
Nakamura, T.; Shibayama, K.; Nagasato, K.; Matsuo, H.; Tsujihata, M.; Nagataki, S. The efficacy of interferon-alpha treatment in human T-lymphotropic virus type-I-associated myelopathy.Jpn. J. Med.1990,29, 362–367. [Google Scholar] [CrossRef] [PubMed] ...
Long term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunolo... The efficacy of long-term, high dose interferon-α (IFN-α) therapy was studied in seven patients with HTLV-I-associated myelopathy (HAM)...
Human T lymphotropic virus type 1 (HTLV-1) causes disabling and fatal diseases, yet there is no vaccine, no satisfactory treatment, and no means of assessing the risk of disease or prognosis in infected people. Recent research on the molecular virology and immunology of HTLV-1 shows the impor...
Most commonly, infection remains undetected, since it does not cause obvious harm, yet in 4-9% of patients, this infection can be devastating, causing adult T-cell leukemia/lymphoma and/or HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). This review concentrates on all ...
Human T-cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T-cell leukemia/lymphoma (ATLL) and the neurodegenerative disorder HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) (Matsuoka, 2005). HTLV-1 encodes the transactivator protein Tax which is critical...
(HealthDay)—For patients with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy-tropical spastic paraparesis (HAM-TSP), treatment with the humanized anti-CCR4 monoclonal antibody that targets infected cells, mogamulizumab, decreases the n